Methods for assessing the risk of adverse events upon treatment with igg4 antibodies

The method of any one of the preceding claims, wherein the therapeutic antibody is an antibody that binds a molecule selected from the group consisting of:

• an integrin subunit, such as VLA-4, CD4, intercellular adhesion molecule 1 (ICAM-1), Fc gamma RI, Fc gamma RII, beta2 microglobulin, CD15, CD33 and low density lipoprotein (LDL) receptors.

The method of any of the preceding claims, wherein the adverse event is a viral disease and the antigen is a viral antigen.

The method of any one of the preceding claims, wherein the individual is an immuno-compromised individual.

The method of any one of the preceding claims, wherein the sample is a blood sample, such as a serum sample.

The method of any of the preceding claims, wherein the assay in step b) comprises a qualitative detection of the presence of said circulating IgG4 antibodies.

The method of any of the preceding claims, wherein the assay in step b) comprises a quantitative detection of the presence of said circulating IgG4 antibodies.

A kit comprising

• a) one or more of the materials required for performing the method of any one of the preceding claims, and
• b) instructions describing or referring to the method of any one of the preceding claims.

A kit comprising:

• a) an anti-human IgG4 antibody, and
• b) an antigen known or suspected to be associated with a causative agent of an adverse event, preferably an antigen of an infectious agent, more preferably a virus particle or an antigen of a virus, such as a JC virus particle or an antigen of a JC virus.